Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 19:01
07/22/20
07/22
19:01
07/22/20
19:01
BCOV

Brightcove

$8.09 /

+0.01 (+0.12%)

, NTGR

Netgear

$29.94 /

-0.24 (-0.80%)

, EFX

Equifax

$168.03 /

+1.77 (+1.06%)

, HLX

Helix Energy

$3.82 /

-0.11 (-2.80%)

, TSLA

Tesla

$1,590.58 /

+24.64 (+1.57%)

, WHR

Whirlpool

$147.20 /

+3.38 (+2.35%)

, ENTX

Entera Bio

$1.91 /

-0.04 (-2.05%)

, FHN

First Horizon

$9.29 /

-0.22 (-2.31%)

, TRN

Trinity Industries

$21.30 /

+0.045 (+0.21%)

, SLM

Sallie Mae

$7.10 /

+0.07 (+1.00%)

, KMI

Kinder Morgan

$14.87 /

-0.22 (-1.46%)

, ALGN

Align Technology

$317.70 /

+2.52 (+0.80%)

, MSFT

Microsoft

$211.71 /

+2.91 (+1.39%)

, CMG

Chipotle

$1,182.66 /

+19.28 (+1.66%)

, LVS

Las Vegas Sands

$46.83 /

-1.13 (-2.36%)

, JMIA

Jumia Technologies

$10.37 /

+1.395 (+15.54%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WHR Whirlpool
$147.20 /

+3.38 (+2.35%)

TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

TRN Trinity Industries
$21.30 /

+0.045 (+0.21%)

SLM Sallie Mae
$7.10 /

+0.07 (+1.00%)

NTGR Netgear
$29.94 /

-0.24 (-0.80%)

MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

LVS Las Vegas Sands
$46.83 /

-1.13 (-2.36%)

KMI Kinder Morgan
$14.87 /

-0.22 (-1.46%)

JMIA Jumia Technologies
$10.37 /

+1.395 (+15.54%)

HLX Helix Energy
$3.82 /

-0.11 (-2.80%)

FHN First Horizon
$9.29 /

-0.22 (-2.31%)

ENTX Entera Bio
$1.91 /

-0.04 (-2.05%)

EFX Equifax
$168.03 /

+1.77 (+1.06%)

CMG Chipotle
$1,182.66 /

+19.28 (+1.66%)

BCOV Brightcove
$8.09 /

+0.01 (+0.12%)

ALGN Align Technology
$317.70 /

+2.52 (+0.80%)

BCOV Brightcove
$8.09 /

+0.01 (+0.12%)

NTGR Netgear
$29.94 /

-0.24 (-0.80%)

05/19/20 Deutsche Bank
Netgear resumed with a Hold at Deutsche Bank
03/30/20 BWS Financial
Netgear upgraded to Buy from Neutral at BWS Financial
02/07/20 BWS Financial
BWS downgrades Netgear on pricing pressure from Google, Amazon
02/07/20 BWS Financial
Netgear downgraded to Neutral from Buy at BWS Financial
EFX Equifax
$168.03 /

+1.77 (+1.06%)

07/10/20 Exane BNP Paribas
Equifax downgraded to Neutral from Outperform at Exane BNP Paribas
06/10/20 Barclays
Equifax price target raised to $175 from $110 at Barclays
06/09/20 JPMorgan
Equifax price target raised to $195 from $150 at JPMorgan
06/09/20 Wells Fargo
Equifax price target raised to $210 from $175 at Wells Fargo
HLX Helix Energy
$3.82 /

-0.11 (-2.80%)

05/28/20 BofA
Liberty Oilfield Services, Helix Energy, Helmerich & Payne upgraded at BofA
05/28/20 BofA
Helix Energy upgraded to Buy from Neutral at BofA
03/17/20 Capital One
Helix Energy downgraded to Equalweight from Overweight at Capital One
03/13/20 Piper Sandler
Helix Energy downgraded to Neutral from Overweight at Piper Sandler
TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

07/22/20 Credit Suisse
Clear focus in Tesla Q2 on GAAP EPS, says Credit Suisse
07/22/20 JPMorgan
Tesla now worth more than Toyota, Volkswagen combined, says JPMorgan
07/22/20 BofA
BofA, despite target boost, says Tesla rally not supported by fundamentals
07/21/20 GLJ Research
Tesla offered discounts to hit China delivery numbers, says GLJ Research
WHR Whirlpool
$147.20 /

+3.38 (+2.35%)

07/15/20 Raymond James
Raymond James says AHAM reports 'core 6' U.S. shipments essentially flat in June
07/10/20 JPMorgan
Whirlpool price target raised to $158 from $124 at JPMorgan
06/23/20 Credit Suisse
Whirlpool price target raised to $103 from $90 at Credit Suisse
06/23/20 Deutsche Bank
Whirlpool price target lowered to $109 from $115 at Deutsche Bank
ENTX Entera Bio
$1.91 /

-0.04 (-2.05%)

FHN First Horizon
$9.29 /

-0.22 (-2.31%)

07/20/20 Evercore ISI
First Horizon upgraded to Outperform from In Line at Evercore ISI
04/01/20 Keefe Bruyette
First Horizon upgraded to Outperform from Market Perform at Keefe Bruyette
03/25/20 Stephens
First Horizon upgraded to Overweight from Equal Weight at Stephens
03/02/20 Baird
Baird upgrades Regions Financial, Fifth Third, First Horizon to Outperform
TRN Trinity Industries
$21.30 /

+0.045 (+0.21%)

01/14/20 Wells Fargo
Trinity Industries downgraded to Underweight from Overweight at Wells Fargo
11/08/19 Susquehanna
Trinity Industries downgraded to Neutral from Positive at Susquehanna
SLM Sallie Mae
$7.10 /

+0.07 (+1.00%)

07/15/20 JPMorgan
Sallie Mae downgraded to Neutral on rising delinquencies at JPMorgan
07/15/20 JPMorgan
Sallie Mae downgraded to Neutral from Overweight at JPMorgan
05/14/20 BMO Capital
BMO downgrades Sallie Mae amid college opening, election uncertainty
05/14/20 BMO Capital
Sallie Mae downgraded to Market Perform from Outperform at BMO Capital
KMI Kinder Morgan
$14.87 /

-0.22 (-1.46%)

07/07/20
Fly Intel: Top five analyst downgrades
07/06/20 Goldman Sachs
Kinder Morgan downgraded to Sell from Neutral at Goldman Sachs
05/18/20 BofA
Plains All American, GP Holdings cut to Underperform at BofA
04/07/20 Mizuho
Kinder Morgan price target lowered to $20 from $23 at Mizuho
ALGN Align Technology
$317.70 /

+2.52 (+0.80%)

07/20/20 BofA
Align Technology downgraded to Underperform from Neutral at BofA
06/12/20 OTR Global
Align Technology upgraded to Positive from Mixed at OTR Global
06/12/20 Stifel
Align Technology price target raised to $300 from $275 at Stifel
05/22/20 Stifel
Align Technology price target raised to $275 after survey at Stifel
MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

07/21/20 Sidoti
AudioCodes downgraded to Neutral from Buy at Sidoti
07/21/20 Wedbush
Wedbush bullish on Microsoft ahead of earnings, expects Azure strength
07/20/20 Raymond James
Microsoft price target raised to $225 from $208 at Raymond James
07/20/20 Stifel
Microsoft price target raised to $215 from $200 at Stifel
CMG Chipotle
$1,182.66 /

+19.28 (+1.66%)

07/20/20 Morgan Stanley
Chipotle price target raised to $688 from $630 at Morgan Stanley
07/20/20 Truist
Chipotle price target raised to $1,336 from $946 at SunTrust
07/20/20 RBC Capital
Chipotle price target raised to $1,125 from $783 at RBC Capital
07/16/20 KeyBanc
Chipotle price target raised to $1,250 from $1,125 at KeyBanc
LVS Las Vegas Sands
$46.83 /

-1.13 (-2.36%)

05/21/20
Fly Intel: Top five analyst upgrades
05/21/20 Credit Suisse
Credit Suisse upgrades Las Vegas Sands to Outperform with $58 target
05/21/20 Credit Suisse
Las Vegas Sands assumed with an Outperform from Neutral at Credit Suisse
05/06/20 Roth Capital
Las Vegas Sands price target lowered to $52 from $69 at Roth Capital
JMIA Jumia Technologies
$10.37 /

+1.395 (+15.54%)

05/14/20 Stifel
Jumia Technologies downgraded to Hold from Buy at Stifel
03/25/20 Berenberg
Jumia Technologies downgraded to Hold from Buy at Berenberg
02/26/20 RBC Capital
Jumia Technologies price target lowered to $13 from $22 at RBC Capital
02/25/20 Stifel
Jumia Technologies price target lowered to $8 from $10 at Stifel
WHR Whirlpool
$147.20 /

+3.38 (+2.35%)

TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

TRN Trinity Industries
$21.30 /

+0.045 (+0.21%)

SLM Sallie Mae
$7.10 /

+0.07 (+1.00%)

NTGR Netgear
$29.94 /

-0.24 (-0.80%)

MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

LVS Las Vegas Sands
$46.83 /

-1.13 (-2.36%)

KMI Kinder Morgan
$14.87 /

-0.22 (-1.46%)

HLX Helix Energy
$3.82 /

-0.11 (-2.80%)

FHN First Horizon
$9.29 /

-0.22 (-2.31%)

EFX Equifax
$168.03 /

+1.77 (+1.06%)

CMG Chipotle
$1,182.66 /

+19.28 (+1.66%)

BCOV Brightcove
$8.09 /

+0.01 (+0.12%)

ALGN Align Technology
$317.70 /

+2.52 (+0.80%)

  • 14
    Feb
WHR Whirlpool
$147.20 /

+3.38 (+2.35%)

TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

LVS Las Vegas Sands
$46.83 /

-1.13 (-2.36%)

KMI Kinder Morgan
$14.87 /

-0.22 (-1.46%)

EFX Equifax
$168.03 /

+1.77 (+1.06%)

CMG Chipotle
$1,182.66 /

+19.28 (+1.66%)

ALGN Align Technology
$317.70 /

+2.52 (+0.80%)

WHR Whirlpool
$147.20 /

+3.38 (+2.35%)

TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

TRN Trinity Industries
$21.30 /

+0.045 (+0.21%)

SLM Sallie Mae
$7.10 /

+0.07 (+1.00%)

NTGR Netgear
$29.94 /

-0.24 (-0.80%)

MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

LVS Las Vegas Sands
$46.83 /

-1.13 (-2.36%)

KMI Kinder Morgan
$14.87 /

-0.22 (-1.46%)

HLX Helix Energy
$3.82 /

-0.11 (-2.80%)

FHN First Horizon
$9.29 /

-0.22 (-2.31%)

EFX Equifax
$168.03 /

+1.77 (+1.06%)

CMG Chipotle
$1,182.66 /

+19.28 (+1.66%)

ALGN Align Technology
$317.70 /

+2.52 (+0.80%)

WHR Whirlpool
$147.20 /

+3.38 (+2.35%)

TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

SLM Sallie Mae
$7.10 /

+0.07 (+1.00%)

MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

LVS Las Vegas Sands
$46.83 /

-1.13 (-2.36%)

KMI Kinder Morgan
$14.87 /

-0.22 (-1.46%)

JMIA Jumia Technologies
$10.37 /

+1.395 (+15.54%)

EFX Equifax
$168.03 /

+1.77 (+1.06%)

CMG Chipotle
$1,182.66 /

+19.28 (+1.66%)

ALGN Align Technology
$317.70 /

+2.52 (+0.80%)

TSLA Tesla
$1,590.58 /

+24.64 (+1.57%)

MSFT Microsoft
$211.71 /

+2.91 (+1.39%)

Hot Stocks
Entera Bio reports 'highly encouraging' oral PTH market survey results » 18:50
07/22/20
07/22
18:50
07/22/20
18:50
ENTX

Entera Bio

$1.91 /

-0.04 (-2.05%)

Entera Bio announced the…

Entera Bio announced the results from two primary market research studies of clinicians who treat osteoporosis patients. The studies were conducted by a third-party firm with a goal of gaining a better understanding of the perceived value and potential market penetration of an orally-delivered parathyroid hormone product in the treatment of osteoporosis. The survey populations were comprised of clinicians who frequently prescribe osteoporosis products including endocrinologists, gynecologists, orthopedists, and general practitioners, with over 70% of their osteoporosis patients having moderate to severe osteoporosis. One study surveyed clinicians in the U.S., Canada, and Europe, and the second surveyed clinicians in Japan. In the two studies, physicians were presented with a description of an oral PTH product that provides similar efficacy and safety of injectable PTH without the need for daily subcutaneous injections. The responses to the prospect of prescribing an oral PTH were overwhelmingly positive, driven by expected improvements in patient compliance, ease of administration, and without injection site discomfort. Physicians also considered reduced costs to patients and payers to be important features. Entera's EB613 oral PTH is currently in Phase 2 clinical development for the treatment of osteoporosis, a multi-billion dollar global market. "We are very pleased with the data from this important global market survey which very clearly validates the value proposition of our lead drug candidate, EB613. Due to the high cost, inconvenience, and pain associated with injectable osteoanabolic products, which are currently the standard of care for treating moderate to severe osteoporosis, it is estimated that only 5% of patients with severe osteoporosis actually receive treatment for their disease," stated Entera CEO Adam Gridley. "The results of this market analysis confirm Entera's view that an oral PTH tablet meets an unmet physician and patient need and can potentially grow the number of patients receiving treatment. Remarkably, approximately 45% of the participating physicians indicated the oral PTH would be their first line treatment choice for their patients with severe osteoporosis."

ShowHide Related Items >><<
ENTX Entera Bio
$1.91 /

-0.04 (-2.05%)

Syndicate
Entera Bio files $100M mixed securities shelf  17:29
07/13/20
07/13
17:29
07/13/20
17:29
ENTX

Entera Bio

$1.84 /

+0.04 (+2.22%)

 
ShowHide Related Items >><<
ENTX Entera Bio
$1.84 /

+0.04 (+2.22%)

Hot Stocks
Entera Bio provides update on EB613 trial » 08:34
07/07/20
07/07
08:34
07/07/20
08:34
ENTX

Entera Bio

$1.76 /

-0.025 (-1.40%)

Entera Bio announced…

Entera Bio announced receipt of approval from the Institutional Review Boards, or IRBs, at the clinical sites for the amendment to its Phase 2 protocol to include the testing of higher doses of EB613. The amendment was submitted after the analysis of the interim Phase 2 biomarker and safety data supported the evaluation of a higher dose of EB613 in the trial. The interim readout demonstrated statistically significant effects on the P1NP biomarker after one month of treatment compared to the placebo, and meaningful increases at months two and three compared to the placebo with the highest EB613 dose. There was also a dose response at one month, with those trends continuing at two months. The two lower doses demonstrated suboptimal increases and therefore, have been discontinued in the amended protocol. Sites have restarted new patient enrollment to include the 2.5mg dose, 1.5mg dose and placebo. There are currently 106 patients enrolled out of the targeted 160 patients in the trial, including the new high-dose group. The company expects to complete enrollment for the trial in Q3.

ShowHide Related Items >><<
ENTX Entera Bio
$1.76 /

-0.025 (-1.40%)

Over a month ago
Syndicate
Entera Bio files to sell 9.6M ordinary shares for holders  17:13
06/05/20
06/05
17:13
06/05/20
17:13
ENTX

Entera Bio

$1.96 /

+0.04 (+2.08%)

 
ShowHide Related Items >><<
ENTX Entera Bio
$1.96 /

+0.04 (+2.08%)

Hot Stocks
Entera Bio's osteoporosis candidate shows "significant" Phase 2 results » 06:36
05/21/20
05/21
06:36
05/21/20
06:36
ENTX

Entera Bio

$2.65 /

-0.33 (-11.07%)

Entera Bio announced…

Entera Bio announced interim limited biomarker data from the ongoing Phase 2 clinical trial of EB613 in osteoporosis patients. The study demonstrated "statistically significant effects" on the P1NP biomarker after one month of treatment vs. placebo, and meaningful increases at months two and three vs. placebo with the highest EB613 dose. There was also a dose response at one month, with those trends continuing at two months. The two lower doses likely do not warrant further clinical advancement. The company believes that the maximum efficacious dose has not yet been achieved. Based on the favorable safety profile for patients on EB613 in the ongoing Phase 2 study, the company intends to evaluate additional doses greater than 1.5mg to advance into a potential Phase 3 study, if appropriate. P1NP is an important biomarker of bone formation and increases and maintenance of BMD are widely accepted as indicators of an overall improvement of the underlying disease. There were no serious product-related adverse events, and the overall safety profile of EB613 was favorable. "We saw a meaningful increase in the bone marker data for the patients enrolled in our Phase 2 clinical trial of EB613 after just one month of treatment with the 1.5mg dose, the highest dose we tested, with no CTX increases relative to placebo. We believe that these dose responses, and these early positive trends with the highest dose warrant investigating at least one additional higher dose to select for potential Phase 3 development," stated CEO Adam Gridley. "We (...) are targeting completion of enrollment in Q3, subject to any COVID impacts."

ShowHide Related Items >><<
ENTX Entera Bio
$2.65 /

-0.33 (-11.07%)

ENTX Entera Bio
$2.65 /

-0.33 (-11.07%)

Over a quarter ago
Conference/Events
Entera Bio management to meet with Maxim » 04:55
01/29/20
01/29
04:55
01/29/20
04:55
ENTX

Entera Bio

$3.18 /

-0.015 (-0.47%)

Meeting to be held in New…

Meeting to be held in New York on January 29 hosted by Maxim.

ShowHide Related Items >><<
Conference/Events
Entera Bio management to meet with Maxim » 09:59
01/22/20
01/22
09:59
01/22/20
09:59
ENTX

Entera Bio

$2.80 /

+ (+0.00%)

Meeting to be held in New…

Meeting to be held in New York on January 29 hosted by Maxim.

ShowHide Related Items >><<
Conference/Events
EBDF Group to hold a conference » 04:55
01/15/20
01/15
04:55
01/15/20
04:55
A

Agilent

$88.02 /

+0.565 (+0.65%)

, AGE

AgeX Therapeutics

$1.85 /

+0.13 (+7.56%)

, ALNY

Alnylam

$118.48 /

+3.68 (+3.21%)

, AZN

AstraZeneca

$50.18 /

+0.5 (+1.01%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BCLI

BrainStorm

$4.34 /

-0.04 (-0.91%)

, ENTX

Entera Bio

$2.78 /

-0.03 (-1.07%)

, DYAI

Dyadic International

$5.50 /

-0.135 (-2.40%)

, DTIL

Precision BioSciences

$13.40 /

-0.12 (-0.89%)

, DD

DuPont

$60.16 /

-0.25 (-0.41%)

, CYCC

Cyclacel Pharmaceuticals

$0.74 /

-0.0549 (-6.91%)

, CTLT

Catalent

$60.34 /

+0.88 (+1.48%)

, COWN

Cowen Group

$16.34 /

-0.2 (-1.21%)

, GMAB

Genmab

$22.44 /

-0.21 (-0.93%)

, IDXG

Interpace Biosciences

$0.62 /

+ (+0.00%)

, LCTX

Lineage Cell Therapeutics

$0.75 /

-0.0146 (-1.92%)

, PHIO

Phio Pharmaceuticals

$0.20 /

+0.0117 (+6.35%)

, PJC

Symbol now PIPR

$0.00 /

+ (+0.00%)

, TNXP

Tonix Pharmaceuticals

$1.48 /

+0.03 (+2.07%)

, TROV

Changed name to CRDF

$1.47 /

+0.15 (+11.41%)

, VCYT

Veracyte

$28.58 /

+0.17 (+0.60%)

, VIE

Viela Bio

$37.10 /

+4.17 (+12.66%)

, PSTV

Plus Therapeutics

$2.81 /

+0.02 (+0.72%)

, RDUS

Radius Health

$20.14 /

+1.77 (+9.64%)

, MRNA

Moderna

$20.01 /

-0.21 (-1.04%)

, MRK

Merck

$89.93 /

+0.5 (+0.56%)

, NAVB

Navidea

$1.49 /

-0.03 (-1.97%)

, NBSE

NeuBase Therapeutics

$6.31 /

-0.19 (-2.92%)

, NVO

Novo Nordisk

$59.62 /

+0.66 (+1.12%)

, NVS

Novartis

$94.47 /

+0.765 (+0.82%)

, OVID

Ovid Therapeutics

$3.59 /

+0.09 (+2.57%)

, STI

Merged to become TFC

$0.00 /

+ (+0.00%)

, XON

Intrexon

$7.20 /

+0.46 (+6.82%)

, SLRX

Salarius Pharmaceuticals

$3.20 /

+0.15 (+4.92%)

, VVUS

VIVUS

$2.72 /

-0.01 (-0.37%)

, SIVB

SVB Financial

$253.42 /

-0.36 (-0.14%)

, VRML

Vermillion

$0.79 /

-0.0453 (-5.39%)

, VKTX

Viking Therapeutics

$7.36 /

+0.045 (+0.62%)

Biotech Showcase 2020…

Biotech Showcase 2020 will be held in San Francisco on January 13-15.

ShowHide Related Items >><<
A Agilent
$88.02 /

+0.565 (+0.65%)

01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Agilent initiated with an Overweight at Wells Fargo
01/06/20 Citi
Agilent initiated with a Neutral at Citi
11/26/19 JPMorgan
Agilent price target raised to $90 from $85 at JPMorgan
AGE AgeX Therapeutics
$1.85 /

+0.13 (+7.56%)

ALNY Alnylam
$118.48 /

+3.68 (+3.21%)

12/18/19 Cantor Fitzgerald
Alnylam price target raised to $176 from $159 at Cantor Fitzgerald
12/17/19 Piper Sandler
Alnylam price target raised to $155 from $145 at Piper Jaffray
11/25/19 Stifel
Alnylam one of few mid-caps with 'plausible large-cap aspirations,' says Stifel
11/25/19 BMO Capital
Alnylam price target raised to $143 from $138 at BMO Capital
AZN AstraZeneca
$50.18 /

+0.5 (+1.01%)

01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
01/13/20 Stifel
Amarin should rally on failure of two potential competitors, says Stifel
01/13/20 JPMorgan
Epanova discontinuation positive for Amarin, says JPMorgan
12/26/19 Stifel
Stifel sees path to $230 for Iqvia shares after 'significant' AstraZeneca win
BAYRY Bayer
$0.00 /

+ (+0.00%)

12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
12/17/19 Berenberg
Bayer upgraded to Buy from Hold at Berenberg
12/17/19 Berenberg
Bayer upgraded to Buy from Hold at Berenberg
10/21/19 Piper Sandler
Piper reiterates Overweight on Crispr Therapeutics with $100 price target
BCLI BrainStorm
$4.34 /

-0.04 (-0.91%)

ENTX Entera Bio
$2.78 /

-0.03 (-1.07%)

DYAI Dyadic International
$5.50 /

-0.135 (-2.40%)

10/16/19 Dawson James
Dyadic International initiated with a Buy at Dawson James
DTIL Precision BioSciences
$13.40 /

-0.12 (-0.89%)

09/16/19 H.C. Wainwright
Precision IND accepted a quarter sooner than expected, says H.C. Wainwright
08/09/19 BTIG
Precision BioSciences initiated with a Buy at BTIG
08/09/19 BTIG
Precision BioSciences initiated with a Buy at BTIG
04/22/19 Jefferies
Precision BioSciences initiated with a Buy at Jefferies
DD DuPont
$60.16 /

-0.25 (-0.41%)

01/14/20
Fly Intel: Top five analyst initiations
01/14/20 BMO Capital
DuPont price target lowered to $82 from $87 at BMO Capital
01/14/20 Gordon Haskett
DuPont initiated with a Buy at Gordon Haskett
01/08/20 Spin-Off Research
DuPont upgraded to Buy from Hold at Spin-Off Research
CYCC Cyclacel Pharmaceuticals
$0.74 /

-0.0549 (-6.91%)

CTLT Catalent
$60.34 /

+0.88 (+1.48%)

10/17/19 Stephens
Catalent resumed with an Overweight at Stephens
08/28/19
Fly Intel: Top five analyst downgrades
08/28/19 Baird
Catalent price target raised to $60 from $50 at Baird
08/28/19
Catalent downgraded to Sector Weight on valuation at KeyBanc
COWN Cowen Group
$16.34 /

-0.2 (-1.21%)

07/23/19 Buckingham
Cowen Group initiated with a Buy at Buckingham
GMAB Genmab
$22.44 /

-0.21 (-0.93%)

01/13/20 Truist
Genmab initiated with a Buy at SunTrust
01/02/20 Guggenheim
Incyte downgraded to Neutral after strong 2019 at Guggenheim
12/12/19 Deutsche Bank
Genmab downgraded to Hold from Buy at Deutsche Bank
10/04/19 Guggenheim
Guggenheim positively biased on Biotech heading into earnings
IDXG Interpace Biosciences
$0.62 /

+ (+0.00%)

09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
LCTX Lineage Cell Therapeutics
$0.75 /

-0.0146 (-1.92%)

PHIO Phio Pharmaceuticals
$0.20 /

+0.0117 (+6.35%)

PJC Symbol now PIPR
$0.00 /

+ (+0.00%)

10/04/19 Buckingham
Piper Jaffray initiated with a Neutral at Buckingham
10/04/19 Buckingham
Piper Jaffray initiated with a Neutral rating at Buckingham
TNXP Tonix Pharmaceuticals
$1.48 /

+0.03 (+2.07%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
04/18/19
Tonix Pharmaceuticals upgraded to Buy at Roth Capital
04/18/19 Roth Capital
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
TROV Changed name to CRDF
$1.47 /

+0.15 (+11.41%)

03/01/19 Maxim
Trovagene price target lowered to $8 from $18 at Maxim
VCYT Veracyte
$28.58 /

+0.17 (+0.60%)

12/04/19 Lake Street
Veracyte answered key question with NanoString pact, says Lake Street
07/31/19
Fly Intel: Top five analyst initiations
07/31/19 Lake Street
Veracyte initiated with a Buy at Lake Street
07/02/19
Fly Intel: Top five analyst initiations
VIE Viela Bio
$37.10 /

+4.17 (+12.66%)

10/28/19 Guggenheim
Guggenheim starts Viela Bio at Buy, makes stock Best Idea
10/28/19 Morgan Stanley
Viela Bio initiated with an Overweight at Morgan Stanley
10/28/19 Cowen
Viela Bio initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Viela Bio initiated with a Buy at Goldman Sachs
PSTV Plus Therapeutics
$2.81 /

+0.02 (+0.72%)

RDUS Radius Health
$20.14 /

+1.77 (+9.64%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
MRNA Moderna
$20.01 /

-0.21 (-1.04%)

01/10/20 Roth Capital
Moderna 'inching closer to a blockbuster CMV vaccine,' says Roth Capital
12/03/19 BofA
Moderna resumed with a Buy at BofA/Merrill
10/25/19 Roth Capital
Moderna initiated with a Buy at Roth Capital
09/13/19 Piper Sandler
Moderna price target raised to $32 from $30 at Piper Jaffray
MRK Merck
$89.93 /

+0.5 (+0.56%)

01/07/20
Fly Intel: Top five analyst initiations
01/07/20 SVB Leerink
OS miss in 1L SCLC 'a disappointing start to 2020' for Merck, says SVB Leerink
01/06/20 RBC Capital
Merck initiated with a Sector Perform at RBC Capital
12/18/19 Morgan Stanley
Morgan Stanley upgrades Major Pharmaceuticals sector view to Attractive
NAVB Navidea
$1.49 /

-0.03 (-1.97%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
NBSE NeuBase Therapeutics
$6.31 /

-0.19 (-2.92%)

11/20/19 Oppenheimer
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
10/29/19 H.C. Wainwright
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
09/24/19 BTIG
NeuBase Therapeutics initiated with a Buy at BTIG
NVO Novo Nordisk
$59.62 /

+0.66 (+1.12%)

01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral on continued insulin headwinds at Guggenheim
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral from Buy at Guggenheim
11/22/19 Pareto
Novo Nordisk downgraded to Hold from Buy at Pareto
11/19/19 Truist
Dicerna price target raised to $28 from $24 at SunTrust
NVS Novartis
$94.47 /

+0.765 (+0.82%)

01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
12/16/19 Evercore ISI
Evercore downgrades Regeneron on Eylea risk from Beovu
12/16/19
Novartis ends development of fevipiprant in asthma after Phase III failure
OVID Ovid Therapeutics
$3.59 /

+0.09 (+2.57%)

09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
09/04/19 RBC Capital
Ovid Therapeutics initiated with an Outperform at RBC Capital
03/10/19 Piper Sandler
Ovid Therapeutics price target lowered to $14 from $20 at Piper Jaffray
STI Merged to become TFC
$0.00 /

+ (+0.00%)

12/09/19 RBC Capital
PNC Financial downgraded to Outperform from Top Pick at RBC Capital
11/20/19 Janney Montgomery Scott
SunTrust downgraded to Neutral from Buy at Janney Montgomery Scott
11/11/19 Janney Montgomery Scott
Janney Montgomery Scott downgrades BB&T to Neutral, says premium may 'flatten'
10/08/19 Jefferies
Jefferies changes five bank ratings after looking into 2020, 2021
XON Intrexon
$7.20 /

+0.46 (+6.82%)

06/18/19 JMP Securities
Surterra cannabinoid pact a positive for Intrexon, says JMP Securities
03/01/19 Northland
Intrexon downgraded to Market Perform from Outperform at Northland
SLRX Salarius Pharmaceuticals
$3.20 /

+0.15 (+4.92%)

VVUS VIVUS
$2.72 /

-0.01 (-0.37%)

SIVB SVB Financial
$253.42 /

-0.36 (-0.14%)

01/09/20 BofA
SVB Financial named top pick for 2020 at BofA
01/09/20 BofA
Amazaon, Wix.com, & SVB Financial added to US 1 List at BofA
01/02/20 Truist
SunTrust raises price targets on select regional banks on improved margins
08/13/19 JPMorgan
JPMorgan sees 'tremendous buying opportunity' into SVB Financial shares
VRML Vermillion
$0.79 /

-0.0453 (-5.39%)

12/16/19
Vermillion management to meet with William Blair
VKTX Viking Therapeutics
$7.36 /

+0.045 (+0.62%)

11/21/19 Truist
Viking posting for VOYAGER includes 'nothing concerning,' says SunTrust
07/15/19 Oppenheimer
Viking Therapeutics initiated with an Outperform at Oppenheimer
06/25/19 Stifel
Viking Therapeutics initiated with a Buy at Stifel
06/25/19 Stifel
Madrigal Pharmaceuticals initiated with a Hold at Stifel
Conference/Events
EBDF Group to hold a conference » 04:55
01/14/20
01/14
04:55
01/14/20
04:55
A

Agilent

$87.45 /

-0.19 (-0.22%)

, AGE

AgeX Therapeutics

$1.72 /

-0.15 (-8.02%)

, ALNY

Alnylam

$114.80 /

-4.57 (-3.83%)

, AZN

AstraZeneca

$49.68 /

-0.17 (-0.34%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BCLI

BrainStorm

$4.38 /

+0.01 (+0.23%)

, ENTX

Entera Bio

$2.81 /

+0.13 (+4.85%)

, DYAI

Dyadic International

$5.64 /

-0.055 (-0.97%)

, DTIL

Precision BioSciences

$13.52 /

-1.19 (-8.09%)

, DD

DuPont

$60.41 /

+0.7 (+1.17%)

, CYCC

Cyclacel Pharmaceuticals

$0.80 /

-0.115 (-12.64%)

, CTLT

Catalent

$59.46 /

+1.77 (+3.07%)

, COWN

Cowen Group

$16.54 /

+0.24 (+1.47%)

, GMAB

Genmab

$22.65 /

-0.02 (-0.09%)

, IDXG

Interpace Biosciences

$0.62 /

-0.0289 (-4.45%)

, LCTX

Lineage Cell Therapeutics

$0.76 /

-0.002 (-0.26%)

, PHIO

Phio Pharmaceuticals

$0.18 /

-0.0225 (-10.95%)

, PJC

Symbol now PIPR

$0.00 /

+ (+0.00%)

, TNXP

Tonix Pharmaceuticals

$1.45 /

-0.14 (-8.81%)

, TROV

Changed name to CRDF

$1.32 /

+0.075 (+6.05%)

, VCYT

Veracyte

$28.41 /

-0.49 (-1.70%)

, VIE

Viela Bio

$32.93 /

+2.84 (+9.44%)

, PSTV

Plus Therapeutics

$2.79 /

-0.05 (-1.76%)

, RDUS

Radius Health

$18.37 /

-1.05 (-5.41%)

, MRNA

Moderna

$20.22 /

+1.12 (+5.86%)

, MRK

Merck

$89.43 /

-0.08 (-0.09%)

, NAVB

Navidea

$1.52 /

+ (+0.00%)

, NBSE

NeuBase Therapeutics

$6.50 /

-0.51 (-7.28%)

, NVO

Novo Nordisk

$58.96 /

+0.27 (+0.46%)

, NVS

Novartis

$93.71 /

-0.165 (-0.18%)

, OVID

Ovid Therapeutics

$3.50 /

-0.35 (-9.09%)

, STI

Merged to become TFC

$0.00 /

+ (+0.00%)

, XON

Intrexon

$6.74 /

+0.3 (+4.66%)

, SLRX

Salarius Pharmaceuticals

$3.05 /

-0.58 (-15.98%)

, VVUS

VIVUS

$2.73 /

-0.065 (-2.33%)

, SIVB

SVB Financial

$253.78 /

+1.99 (+0.79%)

, VRML

Vermillion

$0.84 /

+0.036 (+4.48%)

, VKTX

Viking Therapeutics

$7.31 /

-0.4 (-5.19%)

Biotech Showcase 2020…

Biotech Showcase 2020 will be held in San Francisco on January 13-15.

ShowHide Related Items >><<
A Agilent
$87.45 /

-0.19 (-0.22%)

01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Agilent initiated with an Overweight at Wells Fargo
01/06/20 Citi
Agilent initiated with a Neutral at Citi
11/26/19 JPMorgan
Agilent price target raised to $90 from $85 at JPMorgan
AGE AgeX Therapeutics
$1.72 /

-0.15 (-8.02%)

ALNY Alnylam
$114.80 /

-4.57 (-3.83%)

12/18/19 Cantor Fitzgerald
Alnylam price target raised to $176 from $159 at Cantor Fitzgerald
12/17/19 Piper Sandler
Alnylam price target raised to $155 from $145 at Piper Jaffray
11/25/19 Stifel
Alnylam one of few mid-caps with 'plausible large-cap aspirations,' says Stifel
11/25/19 BMO Capital
Alnylam price target raised to $143 from $138 at BMO Capital
AZN AstraZeneca
$49.68 /

-0.17 (-0.34%)

01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
01/13/20 Stifel
Amarin should rally on failure of two potential competitors, says Stifel
01/13/20 JPMorgan
Epanova discontinuation positive for Amarin, says JPMorgan
12/26/19 Stifel
Stifel sees path to $230 for Iqvia shares after 'significant' AstraZeneca win
BAYRY Bayer
$0.00 /

+ (+0.00%)

12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
12/17/19 Berenberg
Bayer upgraded to Buy from Hold at Berenberg
12/17/19 Berenberg
Bayer upgraded to Buy from Hold at Berenberg
10/21/19 Piper Sandler
Piper reiterates Overweight on Crispr Therapeutics with $100 price target
BCLI BrainStorm
$4.38 /

+0.01 (+0.23%)

ENTX Entera Bio
$2.81 /

+0.13 (+4.85%)

DYAI Dyadic International
$5.64 /

-0.055 (-0.97%)

10/16/19 Dawson James
Dyadic International initiated with a Buy at Dawson James
DTIL Precision BioSciences
$13.52 /

-1.19 (-8.09%)

09/16/19 H.C. Wainwright
Precision IND accepted a quarter sooner than expected, says H.C. Wainwright
08/09/19 BTIG
Precision BioSciences initiated with a Buy at BTIG
08/09/19 BTIG
Precision BioSciences initiated with a Buy at BTIG
04/22/19 Jefferies
Precision BioSciences initiated with a Buy at Jefferies
DD DuPont
$60.41 /

+0.7 (+1.17%)

01/08/20 Spin-Off Research
DuPont upgraded to Buy from Hold at Spin-Off Research
12/18/19 DZ Bank
DuPont upgraded to Buy from Hold at DZ Bank
12/17/19 JPMorgan
IFF shares can rally 50% over three years, says JPMorgan
12/17/19 Jefferies
DuPont price target lowered to $79 from $85 at Jefferies
CYCC Cyclacel Pharmaceuticals
$0.80 /

-0.115 (-12.64%)

CTLT Catalent
$59.46 /

+1.77 (+3.07%)

10/17/19 Stephens
Catalent resumed with an Overweight at Stephens
08/28/19
Fly Intel: Top five analyst downgrades
08/28/19 Baird
Catalent price target raised to $60 from $50 at Baird
08/28/19
Catalent downgraded to Sector Weight on valuation at KeyBanc
COWN Cowen Group
$16.54 /

+0.24 (+1.47%)

07/23/19 Buckingham
Cowen Group initiated with a Buy at Buckingham
GMAB Genmab
$22.65 /

-0.02 (-0.09%)

01/13/20 Truist
Genmab initiated with a Buy at SunTrust
01/02/20 Guggenheim
Incyte downgraded to Neutral after strong 2019 at Guggenheim
12/12/19 Deutsche Bank
Genmab downgraded to Hold from Buy at Deutsche Bank
10/04/19 Guggenheim
Guggenheim positively biased on Biotech heading into earnings
IDXG Interpace Biosciences
$0.62 /

-0.0289 (-4.45%)

09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
LCTX Lineage Cell Therapeutics
$0.76 /

-0.002 (-0.26%)

PHIO Phio Pharmaceuticals
$0.18 /

-0.0225 (-10.95%)

PJC Symbol now PIPR
$0.00 /

+ (+0.00%)

10/04/19 Buckingham
Piper Jaffray initiated with a Neutral at Buckingham
10/04/19 Buckingham
Piper Jaffray initiated with a Neutral rating at Buckingham
TNXP Tonix Pharmaceuticals
$1.45 /

-0.14 (-8.81%)

08/30/19 Roth Capital
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
04/18/19
Tonix Pharmaceuticals upgraded to Buy at Roth Capital
04/18/19 Roth Capital
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
TROV Changed name to CRDF
$1.32 /

+0.075 (+6.05%)

03/01/19 Maxim
Trovagene price target lowered to $8 from $18 at Maxim
VCYT Veracyte
$28.41 /

-0.49 (-1.70%)

12/04/19 Lake Street
Veracyte answered key question with NanoString pact, says Lake Street
07/31/19
Fly Intel: Top five analyst initiations
07/31/19 Lake Street
Veracyte initiated with a Buy at Lake Street
07/02/19
Fly Intel: Top five analyst initiations
VIE Viela Bio
$32.93 /

+2.84 (+9.44%)

10/28/19 Guggenheim
Guggenheim starts Viela Bio at Buy, makes stock Best Idea
10/28/19 Morgan Stanley
Viela Bio initiated with an Overweight at Morgan Stanley
10/28/19 Cowen
Viela Bio initiated with an Outperform at Cowen
10/28/19 Goldman Sachs
Viela Bio initiated with a Buy at Goldman Sachs
PSTV Plus Therapeutics
$2.79 /

-0.05 (-1.76%)

RDUS Radius Health
$18.37 /

-1.05 (-5.41%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
MRNA Moderna
$20.22 /

+1.12 (+5.86%)

01/10/20 Roth Capital
Moderna 'inching closer to a blockbuster CMV vaccine,' says Roth Capital
12/03/19 BofA
Moderna resumed with a Buy at BofA/Merrill
10/25/19 Roth Capital
Moderna initiated with a Buy at Roth Capital
09/13/19 Piper Sandler
Moderna price target raised to $32 from $30 at Piper Jaffray
MRK Merck
$89.43 /

-0.08 (-0.09%)

01/07/20
Fly Intel: Top five analyst initiations
01/07/20 SVB Leerink
OS miss in 1L SCLC 'a disappointing start to 2020' for Merck, says SVB Leerink
01/06/20 RBC Capital
Merck initiated with a Sector Perform at RBC Capital
12/18/19 Morgan Stanley
Morgan Stanley upgrades Major Pharmaceuticals sector view to Attractive
NAVB Navidea
$1.52 /

+ (+0.00%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
NBSE NeuBase Therapeutics
$6.50 /

-0.51 (-7.28%)

11/20/19 Oppenheimer
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
10/29/19 H.C. Wainwright
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
09/24/19 BTIG
NeuBase Therapeutics initiated with a Buy at BTIG
NVO Novo Nordisk
$58.96 /

+0.27 (+0.46%)

01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral on continued insulin headwinds at Guggenheim
01/03/20 Guggenheim
Novo Nordisk downgraded to Neutral from Buy at Guggenheim
11/22/19 Pareto
Novo Nordisk downgraded to Hold from Buy at Pareto
11/19/19 Truist
Dicerna price target raised to $28 from $24 at SunTrust
NVS Novartis
$93.71 /

-0.165 (-0.18%)

01/06/20 JPMorgan
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
12/16/19 Evercore ISI
Evercore downgrades Regeneron on Eylea risk from Beovu
12/16/19
Novartis ends development of fevipiprant in asthma after Phase III failure
OVID Ovid Therapeutics
$3.50 /

-0.35 (-9.09%)

09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
09/04/19 RBC Capital
Ovid Therapeutics initiated with an Outperform at RBC Capital
03/10/19 Piper Sandler
Ovid Therapeutics price target lowered to $14 from $20 at Piper Jaffray
STI Merged to become TFC
$0.00 /

+ (+0.00%)

12/09/19 RBC Capital
PNC Financial downgraded to Outperform from Top Pick at RBC Capital
11/20/19 Janney Montgomery Scott
SunTrust downgraded to Neutral from Buy at Janney Montgomery Scott
11/11/19 Janney Montgomery Scott
Janney Montgomery Scott downgrades BB&T to Neutral, says premium may 'flatten'
10/08/19 Jefferies
Jefferies changes five bank ratings after looking into 2020, 2021
XON Intrexon
$6.74 /

+0.3 (+4.66%)

06/18/19 JMP Securities
Surterra cannabinoid pact a positive for Intrexon, says JMP Securities
03/01/19 Northland
Intrexon downgraded to Market Perform from Outperform at Northland
SLRX Salarius Pharmaceuticals
$3.05 /

-0.58 (-15.98%)

VVUS VIVUS
$2.73 /

-0.065 (-2.33%)

SIVB SVB Financial
$253.78 /

+1.99 (+0.79%)

01/09/20 BofA
SVB Financial named top pick for 2020 at BofA
01/09/20 BofA
Amazaon, Wix.com, & SVB Financial added to US 1 List at BofA
01/02/20 Truist
SunTrust raises price targets on select regional banks on improved margins
08/13/19 JPMorgan
JPMorgan sees 'tremendous buying opportunity' into SVB Financial shares
VRML Vermillion
$0.84 /

+0.036 (+4.48%)

12/16/19
Vermillion management to meet with William Blair
VKTX Viking Therapeutics
$7.31 /

-0.4 (-5.19%)

11/21/19 Truist
Viking posting for VOYAGER includes 'nothing concerning,' says SunTrust
07/15/19 Oppenheimer
Viking Therapeutics initiated with an Outperform at Oppenheimer
06/25/19 Stifel
Viking Therapeutics initiated with a Buy at Stifel
06/25/19 Stifel
Madrigal Pharmaceuticals initiated with a Hold at Stifel

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.